Sir Mortimer B. Davis - Jewish General Hospital
jgh.caTotal trials
60
Active
26
Phase 3
13
Total enrollment
21,040
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 12 of 12 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Aprepitant | — | — | — | — | — | 1 | |
| Androgen deprivation therapy | — | — | — | — | — | 1 | |
| Combination Therapy Arm | — | — | — | — | — | 1 | |
| 18F-fluorocholine PET/CT. | — | — | — | — | — | 1 | |
| Leuprolide Acetate | — | — | — | — | — | 1 | |
| Goserelin Acetate | — | — | — | — | — | 1 | |
| Triptorelin | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| OnabotulinumtoxinA | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Methoxyflurane anesthesia | — | — | — | — | — | 1 |
Next readouts
- 2026-03-07
- 2026-10-01
- 2026-12
- 2027-04
- 2027-05-01
- 2027-06-01
- 2028-01-01
- 2030-01
- 2030-11
Top conditions
- Prostate Cancer17
- Erectile Dysfunction Following Radical Prostatectomy3
- Cancer2
- Post-Thrombotic Syndrome2
- Metastatic Prostate Cancer2
- Head Neck Cancer2
- Deep Venous Thrombosis2
- COVID-192
Frequently asked questions about Sir Mortimer B. Davis - Jewish General Hospital
- How many clinical trials does Sir Mortimer B. Davis - Jewish General Hospital have on ClinicalTrials.gov?
- Sir Mortimer B. Davis - Jewish General Hospital is listed as the lead sponsor on 60 clinical trials in ClinicalTrials.gov, 26 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sir Mortimer B. Davis - Jewish General Hospital's trials are in Phase 3?
- 13 of Sir Mortimer B. Davis - Jewish General Hospital's trials are in Phase 3, spread across 12 active drug programs.
- What therapeutic areas does Sir Mortimer B. Davis - Jewish General Hospital focus on?
- Sir Mortimer B. Davis - Jewish General Hospital's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Cancer, Post-Thrombotic Syndrome, Metastatic Prostate Cancer.
- When are Sir Mortimer B. Davis - Jewish General Hospital's next clinical trial readouts?
- Sir Mortimer B. Davis - Jewish General Hospital has 9 upcoming primary-completion readouts tracked here; the soonest is “Aggressive Smoking Cessation Trial (ASAP)”, expected around 2026-03-07.